CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback